About Diagenode
Diagenode is a company based in Seraing (Belgium) founded in 2003 was acquired by Hologic in March 2021. Diagenode has raised $8.45 million across 12 funding rounds from investors including Hologic, European Union and Capricorn Partners. The company has 99 employees as of March 31, 2020. Diagenode has completed 1 acquisition, including NXT-Dx. Diagenode operates in a competitive market with competitors including Arbor Biotechnologies, Sino Biological, Singleron, GenScript and OncoDNA, among others.
- Headquarter Seraing, Belgium
- Employees 99 as on 31 Mar, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Diagenode
-
Annual Revenue
$19.53 M (USD)9as on Mar 31, 2020
-
Net Profit
-$1 M (USD)-452as on Mar 31, 2020
-
EBITDA
Not available
-
Total Equity Funding
$8.45 M (USD)
in 12 rounds
-
Latest Funding Round
$117.75 K (USD), Grant
Sep 01, 2019
-
Investors
Hologic
& 5 more
-
Employee Count
99
as on Mar 31, 2020
- Investments & Acquisitions
-
Acquired by
Hologic
(Mar 01, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Diagenode
Diagenode has successfully raised a total of $8.45M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $117.75 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diagenode
Diagenode has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Hologic, European Union and Capricorn Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Buyouts are pursued by SRIW as a private equity firm.
|
Locked | Locked | Locked | |
|
Investments are directed by Capricorn Partners into European tech ventures.
|
Locked | Locked | Locked | |
|
Épimède is engaged in investing in high-growth technological SMEs.
|
Locked | Locked | Locked |
Investor details for Diagenode
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagenode
Diagenode has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NXT-Dx.
Investment portfolio details for Diagenode
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Epigenetics services are offered to life science researchers.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Diagenode
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Diagenode
Detailed financials for Diagenode
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diagenode Comparisons
Peer comparison for Diagenode
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diagenode
Diagenode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arbor Biotechnologies, Sino Biological, Singleron, GenScript and OncoDNA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Proprietary reagents for single-cell genetic analysis are developed.
|
Detailed competitors of Diagenode
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagenode
Complete news archive for Diagenode
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagenode
Diagenode was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Diagenode is headquartered in Seraing, Belgium. It is registered at Seraing, Liege, Belgium.
Diagenode is a funded company, having raised a total of $8.45M across 12 funding rounds to date.
As of Mar 31, 2020, the latest employee count at Diagenode is 99.
Annual revenue of Diagenode is $19.53M as on Mar 31, 2020.
Diagenode develops epigenetics solutions and services for life science research. Its flagship product IP-Star Compact is an automated bench-top solution for high-throughput epigenetic sequencing. It has automated protocols for chromatin immunoprecipitation (ChIP), methylated DNA immunoprecipitation (MeDIP), hydroxymethylated DNA immunoprecipitation (hMeDIP), methyl-binding domain protein capture assays (MethylCap), sequential ChIP (Re-ChIP), bisulfite conversion and DNA immunoprecipitation (RNA-IP). In addition, the company provides epigenetic sequencing services, reagents, kits, bioinformatics software associated with IP-Star.
Diagenode's top competitors include Arbor Biotechnologies, Sino Biological and OncoDNA.
Diagenode has made 1 acquisition, including NXT-Dx.
Diagenode has 6 investors. Key investors include Hologic, European Union, Capricorn Partners, SRIW, and Ostbelgieninvest.